SCHEMBL4062306

SCHEMBL4062306

Fc1ccc(C=Cc2nc3ccc(-c4ccccc4)cc3o2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.48
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HTR2A P28223 3/20 0.40
KCNH2 Q12809 3/20 0.40
HTR2C P28335 2/20 0.40
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CYP2D6 P10635 1/20 0.38
UTRN P46939 1/20 0.38
DHODH Q02127 1/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DAGLA Q9Y4D2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062300 1.00 NFE2L2 (0.48) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL4061770 0.91 MEN1 (0.51) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL4061775 0.91 MEN1 (0.51) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL4054692 0.90 METAP2 (0.44) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL4054688 0.90 METAP2 (0.44) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL23064075 0.85 NFE2L2 (0.54) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL26327019 0.85 NFE2L2 (0.54) NFE2L2MEN1ALDH1A1HPGDKMT2A
SCHEMBL4051608 0.83 NFE2L2 (0.40) NFE2L2
SCHEMBL4051602 0.83 NFE2L2 (0.40) NFE2L2
SCHEMBL4051814 0.81 UTRN (0.53) MEN1ALDH1A1HPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NFE2L2 996/4885MEN1 3709/4885ALDH1A1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.